Hospital
Mclaren Oakland
Mclaren Oakland was paid $39.12M by Medicaid between Jan 2018 and Dec 2024, across 380 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoMCLAREN OAKLAND
PONTIAC, MI 48342
PONTIAC, MI 48342
33aNPI1376564088assigned 07/21/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$39.12M
24GClaims1,314,299
24DCodes billed380
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Michigan
Rank by total paid#1 of 7
Median peer was paid$308K
This provider vs. median127×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 169,201 | $5.25M | |
| 2019 | 177,775 | $5.41M | |
| 2020 | 146,859 | $4.36M | |
| 2021 | 201,698 | $5.49M | |
| 2022 | 215,801 | $6.50M | |
| 2023 | 226,926 | $6.52M | |
| 2024incomplete | 176,039 | $5.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 68,015 | 62,897 | $9.08M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 45,028 | 41,205 | $7.95M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 16,093 | 14,936 | $4.34M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 8.1% | 66,148 | 58,312 | $3.18M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 15,096 | 14,427 | $1.47M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.4% | 20,855 | 19,077 | $1.31M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.1% | 5,459 | 3,168 | $816K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.0% | 1,633 | 1,572 | $764K |
| G0378 | Hospital observation service, per hour | 1.7% | 3,898 | 3,074 | $657K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.6% | 1,261 | 1,251 | $634K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 6,027 | 5,858 | $595K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 7,252 | 4,899 | $585K |
368 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 1,816 | $558K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 19,689 | $494K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 23,784 | $467K |
| 58662 | 1.1% | 254 | $435K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,862 | $388K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,247 | $331K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 13,937 | $328K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 6,709 | $317K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,755 | $261K |
| 62323 | <1% | 1,058 | $252K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,468 | $248K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 12,650 | $241K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 15,167 | $197K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,050 | $163K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,045 | $146K |
| 82947 | <1% | 12,821 | $136K | |
| 97162 | <1% | 2,391 | $121K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 892 | $119K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,503 | $102K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,606 | $89K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 35,706 | $83K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 715 | $78K |
| 80061 | Lipid panel | <1% | 7,839 | $69K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,581 | $68K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 460 | $62K |
| 76830 | Ultrasound, transvaginal | <1% | 1,311 | $60K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,164 | $59K |
| 20610 | <1% | 489 | $58K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 310 | $54K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 933 | $52K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 994 | $46K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,889 | $45K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 752 | $45K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 748 | $44K |
| 96417 | <1% | 1,205 | $44K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 721 | $41K |
| 12001 | <1% | 1,439 | $40K | |
| 97161 | <1% | 790 | $40K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 223 | $38K |
| 10060 | <1% | 525 | $37K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 613 | $36K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,264 | $36K |
| 80053 | Comprehensive metabolic panel | <1% | 28,604 | $34K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 576 | $34K |
| 72110 | <1% | 1,301 | $33K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,020 | $33K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,173 | $33K |
| 93971 | <1% | 878 | $32K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 750 | $32K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 646 | $32K |
| 58661 | <1% | 12 | $31K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 852 | $28K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,583 | $28K |
| 97014 | <1% | 3,411 | $27K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 46,685 | $26K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,312 | $26K |
| 96367 | <1% | 820 | $25K | |
| 73562 | <1% | 2,881 | $23K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 67 | $23K |
| 96523 | <1% | 806 | $22K | |
| 96415 | <1% | 507 | $21K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,260 | $20K |
| 73030 | <1% | 3,101 | $20K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,242 | $19K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,419 | $19K |
| 73630 | <1% | 3,947 | $18K | |
| 73610 | <1% | 3,685 | $18K | |
| J3490 | Unclassified drugs | <1% | 32,045 | $18K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,091 | $18K |
| 70486 | <1% | 1,091 | $18K | |
| 76801 | <1% | 417 | $18K | |
| 73130 | <1% | 4,276 | $16K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,248 | $16K |
| 76642 | <1% | 440 | $15K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 53 | $14K |
| 90686 | <1% | 1,286 | $13K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,767 | $12K |
| 64493 | <1% | 27 | $12K | |
| 90670 | <1% | 507 | $12K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,886 | $12K |
| 73502 | <1% | 1,337 | $12K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,030 | $12K |
| 73564 | <1% | 1,571 | $11K | |
| 73110 | <1% | 2,456 | $11K | |
| 76770 | <1% | 221 | $10K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,132 | $10K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 13 | $10K |
| 12011 | <1% | 390 | $9K | |
| 72100 | <1% | 393 | $8K | |
| 64400 | <1% | 84 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,162 | $8K |
| 84439 | <1% | 4,046 | $7K | |
| 82728 | <1% | 2,370 | $7K | |
| 82607 | <1% | 2,115 | $7K | |
| 90651 | <1% | 167 | $7K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 24 | $7K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $7K |
| 74018 | <1% | 1,214 | $7K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 17,225 | $6K |
| 12002 | <1% | 351 | $6K | |
| 29515 | <1% | 118 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,006 | $5K |
| 70496 | <1% | 133 | $5K | |
| 76536 | <1% | 116 | $5K | |
| 97166 | <1% | 145 | $5K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 890 | $5K |
| 87390 | <1% | 623 | $4K | |
| 80074 | <1% | 284 | $4K | |
| 73080 | <1% | 1,034 | $4K | |
| 83550 | <1% | 1,982 | $4K | |
| 93976 | <1% | 84 | $4K | |
| 83540 | <1% | 2,354 | $4K | |
| 43235 | <1% | 12 | $3K | |
| 72131 | <1% | 137 | $3K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 670 | $3K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 22 | $3K |
| 58558 | <1% | 25 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,522 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 292 | $3K |
| 97035 | <1% | 530 | $3K | |
| 10061 | <1% | 27 | $3K | |
| 93017 | <1% | 188 | $3K | |
| 97116 | <1% | 706 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,057 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,002 | $3K |
| 77066 | Tomosynthesis, mammo | <1% | 55 | $3K |
| 86702 | <1% | 638 | $3K | |
| 73590 | <1% | 724 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,916 | $3K |
| 85027 | <1% | 5,667 | $3K | |
| 86803 | <1% | 567 | $2K | |
| 71250 | <1% | 55 | $2K | |
| 86038 | <1% | 677 | $2K | |
| 83735 | <1% | 12,128 | $2K | |
| 82746 | <1% | 638 | $2K | |
| 99195 | <1% | 46 | $2K | |
| 90688 | <1% | 243 | $2K | |
| 82043 | <1% | 1,144 | $2K | |
| 82570 | <1% | 1,021 | $2K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,182 | $2K |
| 73090 | <1% | 425 | $2K | |
| 96411 | <1% | 42 | $2K | |
| 73221 | <1% | 12 | $2K | |
| 85610 | <1% | 13,092 | $2K | |
| 29125 | <1% | 490 | $2K | |
| 71271 | <1% | 25 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,250 | $2K |
| 86140 | <1% | 1,607 | $1K | |
| 86701 | <1% | 591 | $1K | |
| 86900 | <1% | 1,718 | $1K | |
| 87070 | <1% | 1,983 | $1K | |
| 93975 | <1% | 15 | $1K | |
| 84460 | <1% | 5,482 | $1K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 15 | $1K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 114 | $1K |
| 84450 | <1% | 5,472 | $1K | |
| 82565 | <1% | 4,769 | $1K | |
| 83880 | <1% | 2,115 | $1K | |
| 29505 | <1% | 15 | $1K | |
| 74174 | <1% | 15 | $1K | |
| A9270 | Non-covered item or service | <1% | 107,502 | $1K |
| 85730 | <1% | 9,032 | $1K | |
| 93970 | <1% | 12 | $1K | |
| 87186 | <1% | 1,568 | $1K | |
| 87077 | <1% | 1,630 | $1K | |
| 90734 | <1% | 121 | $969.30 | |
| 74022 | <1% | 843 | $967.28 | |
| 72170 | <1% | 1,037 | $966.16 | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 16 | $962.00 |
| 80051 | <1% | 4,316 | $942.78 | |
| 85652 | <1% | 1,741 | $900.87 | |
| 71101 | <1% | 249 | $895.74 | |
| 84520 | <1% | 4,924 | $855.38 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 65 | $852.59 |
| 84702 | <1% | 2,580 | $833.35 | |
| 83615 | <1% | 633 | $817.79 | |
| 77080 | <1% | 14 | $808.82 | |
| 72050 | <1% | 39 | $791.36 | |
| 70498 | <1% | 130 | $734.40 | |
| 84403 | <1% | 136 | $719.68 | |
| 72040 | <1% | 53 | $713.58 | |
| 84100 | <1% | 7,022 | $711.92 | |
| 83690 | <1% | 10,877 | $697.68 | |
| 72128 | <1% | 38 | $671.99 | |
| 81003 | <1% | 10,948 | $657.37 | |
| 90744 | <1% | 122 | $633.44 | |
| 81001 | <1% | 15,745 | $621.26 | |
| 81025 | <1% | 18,309 | $594.89 | |
| 84481 | <1% | 185 | $572.19 | |
| 82550 | <1% | 1,886 | $549.55 | |
| 82652 | <1% | 185 | $547.99 | |
| 77065 | Tomosynthesis, mammo | <1% | 15 | $533.65 |
| 88304 | <1% | 519 | $523.49 | |
| 82150 | <1% | 4,910 | $450.88 | |
| 86235 | <1% | 12 | $430.79 | |
| 86431 | <1% | 317 | $404.45 | |
| 97165 | <1% | 13 | $376.73 | |
| 87634 | <1% | 534 | $368.21 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,325 | $336.19 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 31,346 | $329.08 |
| 72052 | <1% | 12 | $326.00 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 60 | $309.62 |
| 82077 | <1% | 3,247 | $305.96 | |
| 90656 | <1% | 15 | $285.96 | |
| 82247 | <1% | 4,108 | $257.03 | |
| 84550 | <1% | 269 | $256.49 | |
| 86592 | <1% | 138 | $222.37 | |
| 90658 | <1% | 16 | $220.27 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,395 | $196.31 |
| 84165 | <1% | 107 | $192.22 | |
| 86200 | <1% | 64 | $189.04 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,219 | $184.58 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 9,628 | $183.73 |
| 73560 | <1% | 44 | $180.08 | |
| 73700 | <1% | 13 | $178.92 | |
| 87040 | <1% | 3,575 | $170.94 | |
| 99406 | <1% | 12 | $164.75 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 34 | $164.28 |
| 84075 | <1% | 3,592 | $155.21 | |
| 85379 | <1% | 2,475 | $150.32 | |
| 70360 | <1% | 12 | $137.07 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 38 | $134.46 |
| 83605 | <1% | 5,422 | $124.14 | |
| 90715 | <1% | 2,853 | $105.68 | |
| 84484 | <1% | 11,660 | $101.99 | |
| 87081 | <1% | 1,263 | $94.70 | |
| 83930 | <1% | 524 | $91.13 | |
| 83001 | <1% | 12 | $83.96 | |
| 83002 | <1% | 12 | $83.68 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,365 | $78.95 |
| 85046 | <1% | 40 | $73.50 | |
| 80076 | <1% | 52 | $72.65 | |
| 83010 | <1% | 12 | $70.32 | |
| 86706 | <1% | 26 | $66.61 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 15 | $61.58 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 166 | $61.17 |
| 73140 | <1% | 76 | $58.82 | |
| 82248 | <1% | 89 | $57.31 | |
| 85018 | <1% | 791 | $57.28 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,764 | $56.28 |
| 86850 | <1% | 934 | $54.33 | |
| 86376 | <1% | 12 | $50.23 | |
| 82803 | <1% | 309 | $49.46 | |
| 87340 | <1% | 25 | $47.06 | |
| 87205 | <1% | 150 | $44.60 | |
| 80179 | <1% | 810 | $40.22 | |
| 80143 | <1% | 847 | $40.22 | |
| 82040 | <1% | 143 | $38.31 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,939 | $37.82 |
| 83721 | <1% | 27 | $30.79 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 167 | $29.10 |
| 96376 | <1% | 5,806 | $27.95 | |
| 82010 | <1% | 310 | $26.74 | |
| 86901 | <1% | 2,002 | $25.77 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,928 | $24.75 |
| 84703 | <1% | 146 | $24.67 | |
| 82375 | <1% | 182 | $23.37 | |
| 80305 | <1% | 70 | $20.55 | |
| 84436 | <1% | 12 | $20.29 | |
| 87147 | <1% | 152 | $20.24 | |
| 83050 | <1% | 184 | $15.56 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 31,591 | $14.05 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 447 | $13.13 |
| J2704 | Injection, propofol, 10 mg | <1% | 8,083 | $12.00 |
| 82553 | <1% | 193 | $11.28 | |
| 82044 | <1% | 12 | $10.92 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13,627 | $10.05 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 14 | $9.97 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,183 | $8.95 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 7,795 | $8.50 |
| 81015 | <1% | 16 | $8.39 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,845 | $8.17 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 103 | $7.01 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 19,041 | $5.77 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,523 | $4.49 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,511 | $4.42 |
| 84132 | <1% | 145 | $3.94 | |
| 82310 | <1% | 13 | $3.24 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 711 | $2.78 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,144 | $2.65 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 225 | $0.02 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,908 | $0.01 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,517 | $0.01 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,968 | $0.01 |
| 87210 | 0% | 907 | $0.00 | |
| 99152 | 0% | 568 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 2,659 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 1,330 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 1,204 | $0.00 |
| 90633 | 0% | 163 | $0.00 | |
| S5000 | Prescription drug, generic | 0% | 1,248 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 1,160 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 82 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 2,499 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 39 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 556 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 347 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 32 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 96 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 317 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 66 | $0.00 |
| 90714 | 0% | 152 | $0.00 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 0% | 70 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 187 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 181 | $0.00 |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | 0% | 16 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 14 | $0.00 |
| 82374 | 0% | 25 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 12 | $0.00 |
| A4550 | Surgical trays | 0% | 32 | $0.00 |
| 90710 | 0% | 47 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 12 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 12 | $0.00 |
| 84295 | 0% | 38 | $0.00 | |
| 64495 | 0% | 26 | $0.00 | |
| 90707 | 0% | 13 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 27 | $0.00 |
| J3250 | Injection, trimethobenzamide hcl, up to 200 mg | 0% | 19 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 29 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 5,058 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 6,514 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,090 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 1,031 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 56 | $0.00 |
| 97010 | 0% | 2,978 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 5,081 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 956 | $0.00 |
| 73552 | 0% | 13 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 299 | $0.00 |
| 94760 | 0% | 304 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 2,829 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 2,344 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 366 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 608 | $0.00 |
| 90680 | 0% | 223 | $0.00 | |
| 88342 | 0% | 35 | $0.00 | |
| 90698 | 0% | 396 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 110 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 261 | $0.00 |
| 82962 | 0% | 41 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 30 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 916 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 51 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 234 | $0.00 |
| 29130 | 0% | 13 | $0.00 | |
| 96368 | 0% | 150 | $0.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 80 | $0.00 |
| C1769 | Guide wire | 0% | 138 | $0.00 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 101 | $0.00 |
| 64494 | 0% | 27 | $0.00 | |
| 82435 | 0% | 26 | $0.00 | |
| 76870 | 0% | 15 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 179 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 44 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 111 | $0.00 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 63 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 17 | $0.00 |
| 72126 | 0% | 16 | $0.00 | |
| 90696 | 0% | 27 | $0.00 | |
| 76377 | 0% | 67 | $0.00 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 0% | 29 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 44 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 16 | $0.00 |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | 0% | 50 | $0.00 |
| 90716 | 0% | 26 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 57 | $0.00 |
| 90723 | 0% | 12 | $0.00 | |
| 99024 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARCOTTE, LYNN (VP/CFO)
| Provider | Location | Paid |
|---|---|---|
| Mclaren Oakland | Pontiac, MI | $5.73M |
| Mclaren Oakland | Pontiac, MI | $2.33M |
| Mclaren Oakland | Pontiac, MI | $478K |
| Mclaren Oakland | Pontiac, MI | $7K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.